Literature DB >> 32794063

Characterization of 16S rRNA methylase genes in Enterobacterales and Pseudomonas aeruginosa in Athens Metropolitan area, 2015-2016.

Konstantina Nafplioti1, Maria Souli1, Panagiota Adamou1, Eleni Moraitou2, Panagiota Giannopoulou3, Paraskevi Chra4, Maria Damala5, Evangelos Vogiatzakis2, Eleftheria Trikka-Graphakos3, Vasiliki Baka4, Eleni Prifti5, Anastasia Antoniadou1, Irene Galani6,7.   

Abstract

The aim of this study was to characterize the 16S rRNA methylase (RMT) genes in aminoglycoside-resistant Enterobacterales and Pseudomonas aeruginosa isolates in 2015-2016 in hospitals in Athens, Greece. Single-patient, Gram-negative clinical isolates resistant to both amikacin and gentamicin (n = 292) were consecutively collected during a two-year period (2015-2016) in five tertiary care hospitals in Athens. RMT genes were detected by PCR. In all RMT-producing isolates, ESBL and carbapenemase production was confirmed by PCR, and the clonal relatedness and the plasmid contents were also characterized. None of the 138 P. aeruginosa isolates harbored any of the RMT genes surveyed although some were highly resistant to aminoglycosides (MICs > = 512 mg/L). Among 154 Enterobacterales, 31 Providencia stuartii (93.9%), 42 Klebsiella pneumoniae (37.8%), six Proteus mirabilis (75%), and two Escherichia coli (100%) isolates were confirmed as highly resistant to amikacin, gentamicin, and tobramycin with MICs ≥ 512 mg/L, harboring mainly the rmtB (98.8%). All were carbapenemase producers. P. stuartii, P. mirabilis, and E. coli produced VIM-type carbapenemases. K. pneumoniae produced KPC- (n = 34, 81.0%), OXA-48 (n = 4, 9.5%), KPC- and VIM- (n = 3, 7.1%), or only VIM-type (n = 1, 2.4%) enzymes. Two groups of similar IncC plasmids were detected one harboring rmtB1, blaVEB-1, blaOXA-10, and blaTEM-1, and the other additionally blaVIM-1 and blaSHV-5. Among RMT-producing Enterobacterales, rmtB1 predominated and was associated with carbapenemase-encoding gene(s). Similar IncC plasmids carrying a multiresistant region, including ESBL genes, and in the case of VIM-producing isolates, the blaVIM-1, were responsible for this dissemination. The co-dissemination of these genes poses a public health threat.

Entities:  

Keywords:  IncC; KPC; OXA-48; VEB-1; VIM-1; rmtB1

Mesh:

Substances:

Year:  2020        PMID: 32794063     DOI: 10.1007/s10096-020-04006-3

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  28 in total

1.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

Authors:  A-P Magiorakos; A Srinivasan; R B Carey; Y Carmeli; M E Falagas; C G Giske; S Harbarth; J F Hindler; G Kahlmeter; B Olsson-Liljequist; D L Paterson; L B Rice; J Stelling; M J Struelens; A Vatopoulos; J T Weber; D L Monnet
Journal:  Clin Microbiol Infect       Date:  2011-07-27       Impact factor: 8.067

2.  Nosocomial dissemination of Providencia stuartii isolates producing extended-spectrum β-lactamases VEB-1 and SHV-5, metallo-β-lactamase VIM-1, and RNA methylase RmtB.

Authors:  Lamprini Galani; Irene Galani; Maria Souli; Ilias Karaiskos; Emanouella Katsouda; Eleni Patrozou; Fotini Baziaka; Charalampos Paskalis; Helen Giamarellou
Journal:  J Glob Antimicrob Resist       Date:  2013-04-17       Impact factor: 4.035

3.  Prevalence of 16S rRNA methylase genes in Enterobacteriaceae isolates from a Greek university hospital.

Authors:  I Galani; M Souli; T Panagea; G Poulakou; K Kanellakopoulou; H Giamarellou
Journal:  Clin Microbiol Infect       Date:  2012-01-20       Impact factor: 8.067

4.  Revised and updated multiplex PCR targeting acquired 16S rRNA methyltransferases.

Authors:  Laís Lisboa Corrêa; Lara Feital Montezzi; Raquel Regina Bonelli; Beatriz Meurer Moreira; Renata Cristina Picão
Journal:  Int J Antimicrob Agents       Date:  2014-03-06       Impact factor: 5.283

5.  Emergence of Klebsiella pneumoniae co-producing OXA-48, CTX-M-15, and ArmA in Greece.

Authors:  I Galani; G Anagnostoulis; M Chatzikonstantinou; G Petrikkos; M Souli
Journal:  Clin Microbiol Infect       Date:  2016-08-17       Impact factor: 8.067

6.  A general method for detecting and sizing large plasmids.

Authors:  B M Barton; G P Harding; A J Zuccarelli
Journal:  Anal Biochem       Date:  1995-04-10       Impact factor: 3.365

7.  Identification of plasmids by PCR-based replicon typing.

Authors:  Alessandra Carattoli; Alessia Bertini; Laura Villa; Vincenzo Falbo; Katie L Hopkins; E John Threlfall
Journal:  J Microbiol Methods       Date:  2005-06-02       Impact factor: 2.363

8.  In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.

Authors:  Irene Galani; Maria Souli; Konstantina Nafplioti; Panagiora Adamou; Ilias Karaiskos; Helen Giamarellou; Anastasia Antoniadou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-03-01       Impact factor: 3.267

9.  16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides.

Authors:  Yohei Doi; Yoshichika Arakawa
Journal:  Clin Infect Dis       Date:  2007-05-21       Impact factor: 9.079

10.  Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance.

Authors:  Irene Galani; Konstantina Nafplioti; Panagiota Adamou; Ilias Karaiskos; Helen Giamarellou; Maria Souli
Journal:  BMC Infect Dis       Date:  2019-02-15       Impact factor: 3.090

View more
  2 in total

Review 1.  Research Updates of Plasmid-Mediated Aminoglycoside Resistance 16S rRNA Methyltransferase.

Authors:  Weiwei Yang; Fupin Hu
Journal:  Antibiotics (Basel)       Date:  2022-07-07

2.  Increasing Trends of Association of 16S rRNA Methylases and Carbapenemases in Enterobacterales Clinical Isolates from Switzerland, 2017-2020.

Authors:  Claudine Fournier; Laurent Poirel; Sarah Despont; Julie Kessler; Patrice Nordmann
Journal:  Microorganisms       Date:  2022-03-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.